Author: Joshua Cohen
Background:
We developed a model to evaluate treatments for early-stage Hodgkin Lymphoma (HL). The purpose of the model is to project long-term impacts of alternative treatments for HL, taking into account late effects associated with HL treatment.
Methods:
INTERVENTIONS: (1) Chemotherapy alone, and (2) Chemotherapy plus radiation therapy. POPULATION: two prototypical patients: "Patient 1: a 25-year-old male with favorable ESHL (stage IA); Patient 2: a 25-year-old female with unfavorable ESHL (stage IIB)" (from abstract). OUTCOMES: QALYs and LYs.
Results: For Patient 1, CMT was superior to CA (CMT incremental gain = 0.11 QALYs, 0.21 LYs). For Patient 2, CA was superior to CMT (CA incremental gain = 0.37 QALYs, 0.92 LYs).
Conclusion: Therapy benefits depend on patient characteristics.